Brolucizumab (neovascular age-related macular degeneration) – Addendum to Project A23-101

Report documents

1. Addendum

   Brolucizumab (neovascular age-related macular degeneration) – Addendum to Project A23-101

   published on

   02.05.2024

   Document type

   PDF document, 488 kB, EN, not accessible

   DOI-Link

   https://doi.org/10.60584/A24-31_en

   Download file : Addendum (PDF document, 488 kB, EN, not accessible)

Dossier assessment

Additional information

Project details

Project no.

A24-31

Commission

Commission awarded on 18.03.2024 by the Federal Joint Committee (GBA).

Report type

Addendum

Status

Commission completed

Department/Division

Drug Assessment

Topic

Head and nerves

Note

If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.

DOI

https://doi.org/10.60584/A24-31_en

Connected Projects

1. Dossier assessment

   Brolucizumab (neovascular age-related macular degeneration) – Benefit assessment according to §35a Social Code Book V (expiry of the decision)

   Project no.

   A23-101

   Last updated

   02.05.2024

   Status: Commission completed